Skip to main content

Continuing Metformin in Pregnancy Has Little Effect on Nonlive Birth

Medically reviewed by Carmen Pope, BPharm. Last updated on June 18, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, June 18, 2024 -- Continuing metformin and adding insulin in early pregnancy does not significantly alter the risk for nonlive birth or live birth with congenital malformations compared with switching to insulin monotherapy, according to a study published online June 18 in the Annals of Internal Medicine.

Yu-Han Chiu, M.D., Sc.D., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues examined the teratogenicity of metformin use in the first trimester of pregnancy in an observational cohort study of 12,489 pregnant women with pregestational type 2 diabetes receiving metformin monotherapy before the last menstrual period (LMP). Two treatment strategies were assessed: insulin monotherapy (discontinue metformin and initiate insulin within 90 days of LMP; 850 women) and insulin plus metformin (continue metformin and initiate insulin within 90 days of LMP; 1,557 women).

The researchers found that the estimated risk for nonlive birth was 32.7 and 34.3 percent under insulin monotherapy and insulin plus metformin, respectively (risk ratio, 1.02; 95 percent confidence interval, 1.01 to 1.04). The estimated risk for live birth with congenital malformations was 8.0 and 5.7 percent under insulin monotherapy and insulin plus metformin, respectively (risk ratio, 0.72; 95 percent confidence interval, 0.51 to 1.09).

"Current recommendations of switching from metformin to insulin before pregnancy for the management of type 2 diabetes in pregnancy based on teratogenicity concerns may require reconsideration," the authors write.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted June 2024

Read this next

Preoperative SGLT2 Inhibitor Users Have Increased Risk for Postoperative Euglycemic Ketoacidosis

TUESDAY, May 13, 2025 -- Patients using sodium-glucose cotransporter 2 inhibitors (SGLT2i) preoperatively have a slightly increased risk for postoperative euglycemic ketoacidosis...

GLP-1 Receptor Agonists Reduce Alcohol Intake in Patients Treated for Obesity

MONDAY, May 12, 2025 -- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research letter recently published in...

Hyperglycemia, Insulin Resistance in Teens Linked to Worsening Cardiac Damage at Age 24

FRIDAY, May 9, 2025 -- Adolescent hyperglycemia and worsening insulin resistance (IR) are associated with an increased risk for worsening structural and functional cardiac damage...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.